The prognostic impact of perioperative inflammatory status in elderly patients with gastric cancer-Reference-Cited by-同舟云学术

The prognostic impact of perioperative inflammatory status in elderly patients with gastric cancer

Published:2024-03-28 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Toyokawa Takahiro¹,Yoshii Mami¹,Ishidate Takemi¹,Miyamoto Hironari¹,Kuroda Kenji¹,Miki Yuichiro¹,Tamura Tatsuro¹,Lee Shigeru¹,Yashiro Masakazu¹,Maeda Kiyoshi¹

Affiliation:

1. Osaka Metropolitan University Graduate School of Medicine

Abstract

Abstract Background This study aimed to elucidate pre- and postoperative inflammatory prognostic factors, and to evaluate the impact of a combined perioperative inflammation marker for survival in elderly patients with gastric cancer. Methods We retrospectively examined 193 consecutive elderly patients ≥75 years of age who underwent curative gastrectomy for gastric cancer. Preoperative white blood cell (WBC) count (pre-WBC) and C-reactive protein (CRP) level (pre-CRP) and postoperative maximum WBC count (WBCmax) and maximum serum CRP level (CRPmax) were evaluated as prognostic inflammation markers. Results Among prognostic inflammation markers, multivariate analysis revealed pre-CRP and WBCmax as independent prognostic factors (Hazard ratio (HR) 1.645, 95% confidence interval (CI) 1.015–2.652, p = 0.043 and HR 1.913; 95%CI 1.142–3.221, p = 0.014, respectively). Perioperative inflammation score (PIS) constructed with pre-CRP and WBCmax allowed clear classification of patients into three groups for survival, and was revealed as an independent prognostic factor (PIS 1: HR 1.512, 95%CI 0.891–2.607 and PIS 2: HR 3.868, 95%CI 2.032–7.267, p < 0.001). Conclusions High pre-CRP and high WBCmax were independent prognostic factors for OS in elderly patients with gastric cancer after R0 resection. Furthermore, PIS is a promising prognostic indicator and may help surgeons offer optimized treatment strategies for elderly patients with gastric cancer.

Publisher

Research Square Platform LLC

Reference26 articles.

1. 1. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, Abdel-Rahman O, Abdelalim A, Abdoli A, Abdollahpour I, Abdulle ASM et al: Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol. 2019;5(12):1749–1768.

2. 2. Crusz SM, Balkwill FR: Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584–596.

3. 3. Shimada H, Nabeya Y, Okazumi S, Matsubara H, Shiratori T, Aoki T, Sugaya M, Miyazawa Y, Hayashi H, Miyazaki S et al: Elevation of preoperative serum C-reactive protein level is related to poor prognosis in esophageal squamous cell carcinoma. J Surg Oncol. 2003;83(4):248–252.

4. 4. Woo Y, Hyung WJ, Obama K, Kim HI, Pak KH, Son T, Noh SH: Elevated high-sensitivity C-reactive protein, a marker of advanced stage gastric cancer and postgastrectomy disease recurrence. J Surg Oncol. 2012;105(4):405–409.

5. 5. Shrotriya S, Walsh D, Bennani-Baiti N, Thomas S, Lorton C: C-Reactive Protein Is an Important Biomarker for Prognosis Tumor Recurrence and Treatment Response in Adult Solid Tumors: A Systematic Review. PloS one. 2015;10(12):e0143080.